|
1
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Travis WD, Travis LB and Devesa SS: Lung
cancer. Cancer. 75 (Suppl 1):S191–S202. 1995. View Article : Google Scholar
|
|
3
|
Yu DP, Bai LQ, Xu SF, Han M and Wang ZT:
Impact of TNM staging and treatment mode on the prognosis of
non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 31:465–468.
2009.(In Chinese). PubMed/NCBI
|
|
4
|
Quejada MI and Albain KS: Prognostic
factors in non-small cell lung cancer. 2004. View Article : Google Scholar
|
|
5
|
Putila J, Remick SC and Guo NL: Combining
clinical, pathological, and demographic factors refines prognosis
of lung cancer: A population-based study. PLoS One. 6:e174932011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Minamiya Y, Miura M, Hinai Y, Saito H, Ito
M, Imai K, Ono T, Motoyama S and Ogawa J: The CRP 1846T/T genotype
is associated with a poor prognosis in patients with non-small cell
lung cancer. Tumour Biol. 31:673–679. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Asamura H, Chansky K, Crowley J, Goldstraw
P, Rusch VW, Vansteenkiste JF, Watanabe H, Wu YL, Zielinski M, Ball
D, et al: The International Association for the study of lung
cancer lung cancer staging project: Proposals for the revision of
the N descriptors in the forthcoming 8th edition of the TNM
classification for lung cancer. J Thorac Oncol. 10:1675–1684. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ko C: Molecular regulation of deleted in
liver cancer (DLC) protein family. The University of Hong Kong;
Pokfulam, Hong Kong: 2009, View Article : Google Scholar
|
|
10
|
Chan L: Protein interaction and the
subcellular localization control of the deleted in liver cancer
(DLC) family protein. Hku Theses Online. 2008.
|
|
11
|
Basak P, Dillon R, Leslie H, Raouf A and
Mowat MR: The deleted in liver Cancer 1 (Dlc1) tumor suppressor is
haploinsufficient for mammary gland development and epithelial cell
polarity. BMC Cancer. 15:6302015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Song LJ, Liu Q, Meng XR, Li SL, Wang LX,
Fan QX and Xuan XY: DLC-1 is an independent prognostic marker and
potential therapeutic target in hepatocellular cancer. Diagn
Pathol. 11:192016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ortega CE, Seidner Y and Dominguez I:
Mining CK2 in cancer. PLoS One. 9:e1156092014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dötsch MM, Kloten V, Schlensog M, Heide T,
Braunschweig T, Veeck J, Petersen I, Knüchel R and Dahl E: Low
expression of ITIH5 in adenocarcinoma of the lung is associated
with unfavorable patients' outcome. Epigenetics. 10:903–912. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tilghman SL, Townley I, Zhong Q, Carriere
PP, Zou J, Llopis SD, Preyan LC, Williams CC, Skripnikova E,
Bratton MR, et al: Proteomic signatures of acquired letrozole
resistance in breast cancer: Suppressed estrogen signaling and
increased cell motility and invasiveness. Mol Cell Proteomics.
12:2440–2455. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang S, Wang Z, Liu W, Lei R, Shan J, Li
L and Wang X: Distinct prognostic values of S100 mRNA expression in
breast cancer. Sci Rep. 7:397862017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li M, Li S, Liu B, Gu MM, Zou S, Xiao BB,
Yu L, Ding WQ, Zhou PK, Zhou J and Shang ZF: PIG3 promotes NSCLC
cell mitotic progression and is associated with poor prognosis of
NSCLC patients. J Exp Clin Cancer Res. 36:392017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yuan BZ, Jefferson AM, Millecchia L,
Popescu NC and Reynolds SH: Morphological changes and nuclear
translocation of DLC1 tumor suppressor protein precede apoptosis in
human non-small cell lung carcinoma cells. Exp Cell Res.
313:3868–3880. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bokoch GM, Bohl BP and Chuang TH: Guanine
nucleotide exchange regulates membrane translocation of Rac/Rho
GTP-binding proteins. J Biol Chem. 269:31674–31679. 1994.PubMed/NCBI
|
|
22
|
Goodison S, Yuan J, Sloan D, Kim R, Li C,
Popescu NC and Urquidi V: The RhoGAP protein DLC-1 functions as a
metastasis suppressor in breast cancer cells. Cancer Res.
65:6042–6053. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liao YC and Su HL: Deleted in liver
cancer-1 (DLC-1): A tumor suppressor not just for liver. Int J
Biochem Cell Biol. 40:843–847. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Durkin ME, Ullmannova V, Guan M and
Popescu NC: Deleted in liver cancer 3 (DLC-3), a novel Rho
GTPase-activating protein, is downregulated in cancer and inhibits
tumor cell growth. Oncogene. 26:4580–4589. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ching YP, Wong CM, Chan SF, Leung TH, Ng
DC, Jin DY and Ng IO: Deleted in liver cancer (DLC) 2 encodes a
RhoGAP protein with growth suppressor function and is
underexpressed in hepatocellular carcinoma. J Biol Chem.
278:10824–10830. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhong D, Zhang J, Yang S, Soh UJ,
Buschdorf JP, Zhou YT, Yang D and Low BC: The SAM domain of the
RhoGAP DLC1 binds EF1A1 to regulate cell migration. J Cell Sci.
122:414–424. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Healy KD, Hodgson L, Kim TY, Shutes A,
Maddileti S, Juliano RL, Hahn KM, Harden TK, Bang YJ and Der CJ:
DLC-1 suppresses non-small cell lung cancer growth and invasion by
RhoGAP-dependent and independent mechanisms. Mol Carcinog.
47:326–337. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Leung TH, Ching YP, Yam JW, Wong CM, Yau
TO, Jin DY and Ng IO: Deleted in liver cancer 2 (DLC2) suppresses
cell transformation by means of inhibition of RhoA activity. Proc
Natl Acad Sci USA. 102:15207–15212. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim TY, Lee JW, Kim HP, Jong HS, Kim TY,
Jung M and Bang YJ: DLC-1, a GTPase-activating protein for Rho, is
associated with cell proliferation, morphology, and migration in
human hepatocellular carcinoma. Biochem Biophys Res Commun.
355:72–77. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Durkin ME, Avner MR, Huh CG, Yuan BZ,
Thorgeirsson SS and Popescu NC: DLC-1, a Rho GTPase-activating
protein with tumor suppressor function, is essential for embryonic
development. FEBS Lett. 579:1191–1196. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang D, Qian X, Rajaram M, Durkin ME and
Lowy DR: DLC1 is the principal biologically-relevant down-regulated
DLC family member in several cancers. Oncotarget. 7:45144–45157.
2016.PubMed/NCBI
|
|
32
|
Wu PP, Zhu HY, Sun XF, Chen LX, Zhou Q and
Chen J: MicroRNA-141 regulates the tumour suppressor DLC1 in
colorectal cancer. Neoplasma. 62:705–712. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yuan BZ, Miller MJ, Keck CL, Zimonjic DB,
Thorgeirsson SS and Popescu NC: Cloning, characterization, and
chromosomal localization of a gene frequently deleted in human
liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res.
58:2196–2199. 1998.PubMed/NCBI
|
|
34
|
Park H, Cho SY, Kim H, Na D, Han JY, Chae
J, Park C, Park OK, Min S, Kang J, et al: Genomic alterations in
BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.
Proc Natl Acad Sci USA. 112:12492–12497. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Feng H, Zhang Z, Wang X and Liu D:
Identification of DLC-1 expression and methylation status in
patients with non-small-cell lung cancer. Mol Clin Oncol.
4:249–254. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Healy KD, Tai YK, Shutes AT, Bang YJ,
Juliano RL and Der CJ: RhoGAP DLC-1 tumor suppression and aberrant
Rho GTPase activation in lung cancer. Cancer Res. 66:2006.
|
|
37
|
Du X, Qian X, Papageorge A, Schetter AJ,
Vass WC, Liu X, Braverman R, Robles AI and Lowy DR: Functional
interaction of tumor suppressor DLC1 and caveolin-1 in cancer
cells. Cancer Res. 72:4405–4416. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang X, Popescu NC and Zimonjic DB: DLC1
interaction with S100A10 mediates inhibition of in vitro cell
invasion and tumorigenicity of lung cancer cells through a
RhoGAP-independent mechanism. Cancer Res. 71:2916–2925. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ullmannova V and Popescu NC: Expression
profile of the tumor suppressor genes DLC-1 and DLC-2 in solid
tumors. Int J Oncol. 29:1127–1132. 2006.PubMed/NCBI
|
|
40
|
de Tayrac M, Etcheverry A, Aubry M,
Saïkali S, Hamlat A, Quillien V, Le Treut A, Galibert MD and Mosser
J: Integrative genome-wide analysis reveals a robust genomic
glioblastoma signature associated with copy number driving changes
in gene expression. Genes Chromosomes Cancer. 48:55–68. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tang F, Zhang R, He Y, Zou M, Guo L and Xi
T: MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7
and MDA-MB-231 breast cancer cells. PLoS One. 7:e354352012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Vitiello E, Ferreira JG, Maiato H, Balda
MS and Matter K: The tumour suppressor DLC2 ensures mitotic
fidelity by coordinating spindle positioning and cell-cell
adhesion. Nat Commun. 5:58262014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wolosz D, Szparecki G, Wolinska E and
Gornicka B: DLC3 expression in hepatocellular carcinoma. J Pre Clin
Clin Res. 9:105–108. 2015. View Article : Google Scholar
|
|
44
|
Kawai K, Kiyota M, Seike J, Deki Y and
Yagisawa H: START-GAP3/DLC3 is a GAP for RhoA and Cdc42 and is
localized in focal adhesions regulating cell morphology. Biochem
Biophys Res Commun. 364:783–789. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hendrick J and Olayioye MA: Spatial Rho
regulation: Molecular mechanisms controlling the GAP protein DLC3.
Small GTPases. 1–7. 2016.PubMed/NCBI
|
|
46
|
Braun AC, Hendrick J, Eisler SA, Schmid S,
Hausser A and Olayioye MA: The Rho-specific GAP protein DLC3
coordinates endocytic membrane trafficking. J Cell Sci.
128:1386–1399. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Braun AC: Regulation of endocytic membrane
trafficking by the GTPase-activating protein deleted in liver
cancer 3 (DLC3). Uni Stuttgart. 2015.
|
